PERFORMANCE PROBIOTICS
DEAD

Serial Number

87274458

Owner

PathoBiome LLC

Attorney

Brian E. Turung

Filing Date

Dec 20, 2016

Add to watchlist:

No watchlists yet
View on USPTO

PERFORMANCE PROBIOTICS Trademark

Serial Number: 87274458

PERFORMANCE PROBIOTICS is a trademark filed by PathoBiome LLC on December 20, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

PathoBiome LLC (23 trademarks)

Suite 4500
Cleveland, OH 44115

Entity Type: 16

Trademark Details

Filing Date

December 20, 2016

Registration Date

Not Registered

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; nutritional supplements, namely, probiotic compositions; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; all of the foregoing only for human consumption

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 21, 2018 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 18, 2018 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 14, 2017 GNRN
NON-FINAL ACTION E-MAILED
Oct 14, 2017 GNRT
NON-FINAL ACTION WRITTEN
Oct 14, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 25, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 25, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 25, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 27, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 27, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 28, 2016 NWOS